Replies to post #101166 on Biotech Values

[oc631]

the decision by Roche not to run such a study makes perfect sense

I'm not following you on this. RG7128 showed excellent safety and efficiency in Genotypes 2&3 in phase 1 studies. What makes perfect sense?

[oc631]

VRUS/Roche: Hmm…notably absent from the section of yesterday’s VRUS’ PR that enumerates 2010 clinical news (#msg-53137438) is any mention of a phase-2b trial of RG7128 + SoC in genotype-2/3 patients. This is curious insofar as VRUS’ PR from Feb 2010 (#msg-46762882) said:
Quote:
--------------------------------------------------------------------------------
Roche is planning to initiate a Phase 2b study of RG7128 in combination with pegylated interferon and ribavirin in patients with HCV genotypes 2 and 3 later in 2010.
--------------------------------------------------------------------------------

A reasonable inference is that this phase-2b trial is no longer planned. If this is in fact the case, the decision by Roche not to run such a study makes perfect sense, IMO.

FWIW slide 6 in today's c.c. states

GT2/3 phase 2 to initiate 1H11

Looks like the trial has only been pushed back.